Ellen Scordino > DLA Piper LLP (US) > Boston, United States > Lawyer Profile
DLA Piper LLP (US) Offices
![DLA Piper LLP (US) company logo](https://www.legal500.com/wp-content/uploads/sites/13/2022/05/908.jpg?v=1653316305)
33 ARCH STREET
26TH FLOOR
BOSTON MA 02110-1447
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Ellen Scordino
![Ellen Scordino photo](https://www.legal500.com/wp-content/uploads/sites/13/2023/07/53103_1261060.jpg)
Work Department
Intellectual Property and Technology; Patent Litigation; Healthcare; Life Sciences
Position
Partner
Career
Ellen Scordino focuses on patent and trade secret litigation and client counseling in the pharmaceuticals, biologics, diagnostics, biofuels, and medical device industries but has also represented clients in a wide range of other patent and general commercial matters in courts across the country and in arbitrations.
She has particular expertise with Hatch-Waxman and BPCIA litigations and has led trial teams in obtaining favorable judgments and settlements in district courts and inter partes review proceedings. Scordino has also worked extensively with clients to create patent and litigation strategies mindful of regulatory issues and the FDA. She has litigated and counseled clients on matters involving blockbuster drugs, biologics and biosimilars, orphan drugs, PCR technologies, recombinant DNA technologies, medical devices, cannabis, biofuels, and chemistry (including food and consumer good additives).
Memberships
New York Intellectual Property Law Association; Women in Bio; Women in Law Empowerment Forum (WILEF)
Education
J.D., Fordham University School of Law; B.S., Trinity College
Top Tier Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Tax > International tax
- Real estate > Land use/zoning
- Investment fund formation and management > Alternative/hedge funds
- Media, technology and telecoms > Outsourcing
- Intellectual property > Patents: licensing
- Intellectual property > Patents: litigation (International Trade Commission)
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Real estate > Real estate
- International trade > CFIUS
- Government > State attorneys general
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
Firm Rankings
- Media, technology and telecoms > Advertising and marketing: transactional and regulatory
- Insurance > Advice to insurers
- Industry focus > Cannabis
- Dispute resolution > E-discovery
- Tax > Financial products
- Finance > Fintech
- Intellectual property > Patents: litigation (full coverage)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Real estate > Real estate investment trusts (REITs)
- Energy > Renewable/alternative power
- Finance > Structured finance: securitization
- Media, technology and telecoms > Technology transactions
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Tax > US taxes: contentious
- M&A/corporate and commercial > Venture capital and emerging companies
- Labor and employment > Workplace and employment counseling
- Antitrust > Cartel
- Intellectual property > Copyright
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Environment > Environment: regulatory
- Environment > Environment: transactional
- Insurance > Insurance: non-contentious
- Labor and employment > Labor and employment disputes (including collective actions)
- Labor and employment > Labor-management relations
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Media, technology and telecoms > Media and entertainment: transactional
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Dispute resolution > Product liability, mass tort and class action - defense: automotive/transport
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trademarks: litigation
- Tax > US taxes: non-contentious
- Finance > Capital markets: equity offerings
- Antitrust > Civil litigation/class actions: defense
- Real estate > Construction (including construction litigation)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Environment > Environment: litigation
- Dispute resolution > General commercial disputes
- Government > Government contracts
- Dispute resolution > International arbitration
- Investment fund formation and management > Private equity funds (including venture capital)
- Healthcare > Service providers
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Finance > Project finance
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Transport > Rail and road: litigation and regulation
- International trade > CFIUS